Acute Gout Flare Epidemiology Forecast 2025-2034

An acute gout flare occurs when the levels of uric acid in the blood become very high, causing sudden, severe pain and swelling, among other symptoms. The prevalence of gout is estimated to be 1% to 4% worldwide and occurs more commonly in men than in women by 3:1 to 10:1.

Acute Gout Flare Epidemiology Forecast Report Coverage

The “Acute Gout Flare Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of acute gout flare. It projects the future incidence and prevalence rates of acute gout flare across various populations. The study covers age and type as major determinants of the acute gout flare-affected population. The report highlights patterns in the prevalence of acute gout flare over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of acute gout flare in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Acute Gout Flare: Disease Overview

An acute gout flare is usually caused by the accumulation of uric acid crystals. It is characterized by a sudden and severe episode of pain, swelling, and redness in a joint. The excess uric acid in the bloodstream forms sharp crystals, leading to inflammation in the affected joint. Acute gout attacks often come suddenly and can last from a few hours to days. Acute gout attacks can be triggered by factors such as a rich diet (high in purines), alcohol consumption, dehydration, or trauma to the joint.

Acute Gout Flare: Treatment Overview

The treatment for acute gout flare is primarily focused on reducing pain, inflammation, and swelling, along with preventing future attacks by managing uric acid levels in the body. Nonsteroidal anti-inflammatory drugs, such as ibuprofen or naproxen, are commonly taken to address pain and inflammation during an acute flare. Corticosteroids like prednisone are also prescribed to reduce inflammation and manage severe pain. Drugs like allopurinol and febuxostat aid in reducing the production of uric acid in the body, thereby preventing future attacks.

Epidemiology

The acute gout flare epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for acute gout flare by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for acute gout flare and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Gout affects 1% to 4% of people worldwide, with 0.1 to 0.3% of new cases each year. Men are 3 to 10 times more likely to have gout than women. The risk of gout increases with age, becoming more common in people over 80.
• Studies show that some patients experience acute gout attacks 1 to 2 times a year. However, for certain patients, multiple severe attacks occur at short intervals.
• According to a cohort study published in the BMC Primary Care (2023), out of 51,784 patients, 35.9% (18,605) had at least one recurrent gout flare, and 17.4% had it within a year of being diagnosed.
• As per Cross, Marita et al. (2021), around 55.8 million were affected by gout in 2020, with the prevalence 3.26 times higher in men compared to women.

Country-wise Acute Gout Flare Epidemiology

The acute gout flare epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of acute gout flare varies significantly between countries owing to the differences in factors such as lifestyle, diet, genetics, and access to healthcare. Certain populations are reported to have a higher genetic susceptibility to elevated uric acid levels, thereby increasing the likelihood of acute gout attacks. Some studies also suggest that racial minorities in the United States, Han Chinese, New Zealand Maori, and some ethnic groups in Asia have a higher prevalence of gout.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of acute gout flare based on several factors.
• Acute Gout Flare Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of acute gout flare are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of acute gout flare epidemiology in the 8 major markets?
• What will be the total number of patients with acute gout flare across the 8 major markets during the forecast period?
• What was the country-wise prevalence of acute gout flare in the 8 major markets in the historical period?
• Which country will have the highest number of acute gout flare patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of acute gout flare during the forecast period of 2025-2034?
• What are the currently available treatments for acute gout flare?
• What are the disease risks, signs, symptoms, and unmet needs of acute gout flare?

This product will be delivered within 3-5 business days.